Categories
Uncategorized

Pacritinib

 

Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.

It is a macrocyclic protein kinase inhibitor. 

It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).

Routes of administration By mouth

Pacritinib in indicated to treat intermediate or high-risk primary or secondary myelofibrosis and who have platelet levels below 50,000/µL.

The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment.

29% of patients in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to 3% in the standard treatment group.

Leave a Reply

Your email address will not be published. Required fields are marked *